Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells

Hepatology

Volumn 53, Issue 2, 2011, Pages 548-557

  He, Hongwei ^a   Mennone, Albert ^a   Boyer, James L ^a   Cai, Shi Ying ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; CYTOKERATIN 19; CYTOKINE; GELATINASE A; HYDROXYPROLINE; INTERLEUKIN BETA1; MESSENGER RNA; RETINOIC ACID; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CELL PROLIFERATION; CHOLESTASIS; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL;

ANIMALS; BILE ACIDS AND SALTS; BILE DUCTS; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTASIS, INTRAHEPATIC; CHOLESTEROL 7-ALPHA-HYDROXYLASE; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; HEPATOCYTES; HUMANS; LIGATION; LIVER; MALE; MATRIX METALLOPROTEINASE 2; RATS; RATS, SPRAGUE-DAWLEY; SMAD2 PROTEIN; TRETINOIN; URSODEOXYCHOLIC ACID;

EID: 79251527482     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24047     Document Type: Article

References (34)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273.
2. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. HEPATOLOGY 2009; 50: 808-814.
3. Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009; 31: 283-307.
4. Silveira MG, Lindor KD. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis 2008; 12: 425-443.
5. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. HEPATOLOGY 2010; 51: 660-678.
6. Zein CO, Lindor KD. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep 2010; 12: 13-22.
7. Montrone M, Martorelli D, Rosato A, Dolcetti R. Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. Endocr Metab Immune Disord Drug Targets 2009; 9: 113-131.
8. Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis CC. Vitamins as hormones. Horm Metab Res 2007; 39: 71-84.
9. Davis BH, Kramer RT, Davidson NO. Retinoic acid modulates rat Ito cell proliferation, collagen, and transforming growth factor beta production. J Clin Invest 1990; 86: 2062-2070.
10. Pinzani M, Gentilini P, Abboud HE. Phenotypical modulation of liver fat-storing cells by retinoids. Influence on unstimulated and growth factor-induced cell proliferation. J Hepatol 1992; 14: 211-220.
11. Hellemans K, Verbuyst P, Quartier E, Schuit F, Rombouts K, Chandraratna RA, et al. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. HEPATOLOGY 2004; 39: 97-108.
12. Wang H, Dan Z, Jiang H. Effect of all-trans retinoic acid on liver fibrosis induced by common bile duct ligation in rats. J Huazhong Univ Sci Technol Med Sci 2008; 28: 553-557.
13. Cai SY, He H, Nguyen T, Mennone A, Boyer JL. Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. J Lipid Res 2010; 51: 2265-2274.
14. Soroka CJ, Mennone A, Hagey LR, Ballatori N, Boyer JL. Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. HEPATOLOGY 2010; 51: 181-190.
15. Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. HEPATOLOGY 1992; 15: 234-243.
16. Casini A, Pinzani M, Milani S, Grappone C, Galli G, Jezequel AM, et al. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology 1993; 105: 245-253.
17. Van Rossen E, Vander BS, van Grunsven LA, Reynaert H, Bruggeman V, Blomhoff R, et al. Vinculin and cellular retinol-binding protein-1 are markers for quiescent and activated hepatic stellate cells in formalin-fixed paraffin embedded human liver. Histochem Cell Biol 2009; 131: 313-325.
18. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325-329.
19. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966.
20. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, et al. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. HEPATOLOGY 2006; 43: 1013-1021.
21. Poncelet AC, de Caestecker MP, Schnaper HW. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int 1999; 56: 1354-1365.
22. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-629.
23. Svegliati-Baroni G, Ridolfi F, Hannivoort R, Saccomanno S, Homan M, De Minicis S, et al. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 2005; 128: 1042-1055.
24. Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006; 12: 3487-3495.
25. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001; 276: 39411-39418.
26. Kawata K, Kobayashi Y, Souda K, Kawamura K, Sumiyoshi S, Takahashi Y, et al. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. Antioxid Redox Signal 2010; 13: 259-268.
27. Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur J Gastroenterol Hepatol 2005; 17: 137-140.
28. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50: 1721-1734.
29. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-1251.
30. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-1529.
31. Hisamori S, Tabata C, Kadokawa Y, Okoshi K, Tabata R, Mori A, et al. All-trans-retinoic acid ameliorates carbon tetrachloride-induced liver fibrosis in mice through modulating cytokine production. Liver Int 2008; 28: 1217-1225.
32. Parola M, Marra F, Pinzani M. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Aspects Med 2008; 29: 58-66.
33. Dranoff JA, Wells RG. Portal fibroblasts: underappreciated mediators of biliary fibrosis. HEPATOLOGY 2010; 51: 1438-1444.
34. Liu C, Gaca MD, Swenson ES, Vellucci VF, Reiss M, Wells RG. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 2003; 278: 11721-11728.